Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GPR183 | P32249 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14721035 | 0.85 | MCHR1 (0.36) | MCHR1SRD5A2L3MBTL3L3MBTL1RAB9A | |
| SCHEMBL14720608 | 0.81 | HRH3 (0.43) | MCHR1SRD5A2L3MBTL3L3MBTL1GPR183 | |
| SCHEMBL14720920 | 0.81 | HRH3 (0.47) | MCHR1SRD5A2L3MBTL3L3MBTL1GPR183 | |
| SCHEMBL14722284 | 0.78 | HRH3 (0.44) | MCHR1SRD5A2L3MBTL3L3MBTL1GPR183 | |
| SCHEMBL14722836 | 0.78 | HRH3 (0.41) | MCHR1SRD5A2L3MBTL3L3MBTL1GPR183 | |
| SCHEMBL14720913 | 0.75 | GPR183 (0.38) | MCHR1SRD5A2ALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL14722992 | 0.74 | MCHR1 (0.33) | MCHR1 | |
| SCHEMBL12891140 | 0.72 | MAOA (0.45) | ALDH1A1RAB9A | |
| SCHEMBL14720631 | 0.71 | HRH3 (0.45) | MCHR1SRD5A2GPR183NPC1RAB9A | |
| SCHEMBL22804454 | 0.70 | SLC18A3 (0.44) | ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |